- Q1 2024 Vir Biotechnology Inc Earnings Call TranscriptMay 02, 2024$9.18 (+5.03%)Earnings
- Q4 2023 Vir Biotechnology Inc Earnings Call TranscriptFeb 22, 2024$10.3 (+1.88%)Earnings
- Vir Biotechnology Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Vir Biotechnology Inc AASLD Late Breaking Data Update Call TranscriptNov 13, 2023
- Q3 2023 Vir Biotechnology Inc Earnings Call TranscriptNov 02, 2023$8.19 (+5.13%)Earnings
- Vir Biotechnology Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Vir Biotechnology Inc Earnings Call TranscriptAug 03, 2023$13.97 (-0.50%)Earnings
- Vir Biotechnology Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Vir Biotechnology Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Vir Biotechnology Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Vir Biotechnology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM TranscriptJan 10, 2023
- Vir Biotechnology Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 18, 2022
- Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Vir Biotechnology Inc Corporate Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant TranscriptDec 07, 2021
- Vir Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
Vir Biotechnology Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Gena Wang. I'm senior biotech analyst at the Barclays. Welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Vir Biotechnology. With us today, we have Phillip Pang, Chief Medical Officer. We also have Howard Horn, our Chief Financial Officer. So maybe I will hand over to Phillip Pang to give a brief overview before I jump into Q&A.
Thank you, Gena. So as you know, Gena, we've been talking a lot over the last 6 years. So 2023 really poses to be a banner year for Vir. It's a very exciting year. We have 4 clinical programs reading out this year alone in HIV, hepatitis B, hepatitis delta and flu. And each one of these programs can drive transformative potential for patients and value to patients as well as to the company. Behind this clinical pipeline sits a robust research clinical, research
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)